THE DEFINITIVE GUIDE TO AGO TUMOR

Molecular typing relies on molecular genetic testing and isn't however routinely offered. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 may very well be helpful, but a